Over the last several years, major advances in genomics–specifically, the way diseases manifest and develop in the body at the genetic level–are improving our ability to target illness at each stage and improve the patient experience. As a result, we’re sometimes better able to predict which treatments could be most effective by taking into account patients’ genetic make-up, environment and lifestyle. Perhaps the best example of this approach is CART-19 (University of Pennsylvania)
RNA interference in animals involves small double-stranded RNA molecules called siRNA. These molecules are valuable tools for studying single gene function in both in vivo and in vitro settings and are also considered a promising class of therapeutics. SiRNA delivery systems fall into two categories: viral and non-viral, including peptides, polymers, and lipids. Studies using synthetic or plasmid-encoded siRNA show its antiviral effects against various viruses, including SARS-CoV. Learn more about siRNA for Treatment of SARS-CoV-2: https://sars-cov-2.creative-biolabs.com/sirna-for-the-treatment-of-sars-cov2.htm
BioNTech, which co-developed a revolutionary mRNA covid-19 vaccine in partnership with Pfizer, hopes to revolutionise another area of pharmaceuticals: vaccine manufacturing. It is developing vaccine factories to sit inside a series of standard metal shipping containers, which it plans to send to parts of the world that lack their own vaccine-manufacturing capabilities-notably Africa.
Each facility, BioNTech says, will be able to produce up to 60m doses of covid vaccines and other vaccines each year, and will cost "significantly less" than conventional factories. If so, this could be the future of drugmaking.
https://www.economist.com/science-and-technology/biontech-plans-to-make-vaccines-in-shipping-containers/
"Great ideas, research and innovation can come from anyone – so often the best ideas do not have a voice. IdeaSpies provides a platform for people to share ideas that create a better world"
IdeaSpies
Sabra Brock
Max Berghouse
